ENDP
Endo International plcNASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Fri, Sep. 23, 9:14 AM
    | Fri, Sep. 23, 9:14 AM | 1 Comment
  • Fri, Sep. 23, 8:35 AM
    • Endo International plc (ENDPannounces that its Board of Directors has named Paul V. Campanelli President and Chief Executive Officer, effective immediately. Mr. Campanelli currently serves as President of Endo's Generic and OTC drugs business, Par Pharmaceutical, which accounts for ~60% of Endo's total revenues through the first half of 2016.
    • Campanelli joined Endo in 2015 following Endo's acquisition of Par, where he had served as CEO since 2012.
    • Shares up 7% premarket
    | Fri, Sep. 23, 8:35 AM | 1 Comment
  • Fri, Aug. 19, 8:09 AM
    • Luminex (NASDAQ:LMNX) upgraded to Neutral from Underweight by JPMorgan. Price target raised to $22 (0% upside) from $18.
    • Valeant Pharmaceuticals (NYSE:VRX) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $42 (45% upside) from $33. Upgraded to Neutral from Underperform by Mizuho Securities. Price target raised to $25 (14% downside risk) from $11.
    • AveXis (NASDAQ:AVXS) upgraded to Outperform from Market Perform by Wells Fargo. Upgraded to Buy from Hold with a $42 (2% upside) price target by Jefferies.
    • Histogenics (NASDAQ:HSGX) upgraded to Buy from Neutral with a $3.50 (10% upside) price target by BTIG Research.
    • Endo International (NASDAQ:ENDP) upgraded to Buy from Neutral by Mizuho Securities. Price target raised to $29 (26% upside) from $16.
    • Cerulean Pharma (NASDAQ:CERU) downgraded to Market Perform from Outperform by Leerink Swann. Downgraded to Neutral from Buy by Janney Capital. Reiterated Buy by Roth Capital. Price target lowered to $2.50 (108% upside) from $9.00.
    • HMS Holdings (NASDAQ:HMSY) downgraded to Hold from Buy by Jefferies. Price target lowered to $19 (14% downside risk) from $23.
    • Mirna Therapeutics (NASDAQ:MIRN) downgraded to Neutral from Buy by Citigroup. Price target lowered to $4.50 (50% upside) from $7.00.
    • Concordia International (NASDAQ:CXRX) downgraded to Hold from Buy by GMP Securities. Maintained at Neutral but price target lowered to $13 (36% upside) from $26 by Goldman Sachs. Downgraded to Underperform from Sector Perform with a $7.80 (18% downside risk) price target by CIBC.
    • Pernix Therapeutics (NASDAQ:PTX) downgraded to Hold from Buy by Brean Capital.
    | Fri, Aug. 19, 8:09 AM | 21 Comments
  • Fri, Aug. 12, 7:39 AM
    | Fri, Aug. 12, 7:39 AM
  • Tue, Aug. 9, 2:17 PM
    • Endo International (ENDP +20.6%) surges to three-month highs after reporting Q2 earnings and a 25% Y/Y revenue increase that beat Wall Street expectations, boosted by the acquisition of Par Pharmaceutical.
    • Par helped boost sales of Endo's U.S. generic drugs by 67% Y/Y, masking a 5% decline in the generics base business, but management already had warned about the drop as older generics face pricing pressures from increasing competition.
    • Endo says Q2 delivered results across all its businesses that are on-track or ahead of company expectations for the quarter, as it reaffirms FY 2016 guidance for EPS of $4.50-$4.80 vs. $4.54 analyst consensus estimate and sees full-year revenues of $3.87B-$4.03B vs. $3.93B consensus.
    • Analysts at Goldman Sachs and Deutsche Bank respond with respective stock price target increases to $22 and $31, while Mizuho Securities added that "business now appears more stable and less risky."
    • Citi's Liav Abraham says Endo’s relatively uneventful quarter alleviates some caution around the stock following three consecutive quarterly earnings of negative surprises.
    • Endo also says Joseph Ciaffoni, a former senior VP of Biogen's Global Specialty Medicines Group, is joining the company as president of its U.S. Branded Pharmaceuticals unit, effective Aug. 15.
    | Tue, Aug. 9, 2:17 PM | 2 Comments
  • Tue, Aug. 9, 12:46 PM
    | Tue, Aug. 9, 12:46 PM
  • Tue, Aug. 9, 11:00 AM
    | Tue, Aug. 9, 11:00 AM
  • Tue, Aug. 9, 9:19 AM
    | Tue, Aug. 9, 9:19 AM | 2 Comments
  • Mon, Aug. 8, 4:40 PM
    • Endo (NASDAQ:ENDP): Q2 EPS of $0.86 beats by $0.12.
    • Revenue of $921M (+25.3% Y/Y) beats by $56.66M.
    • Shares +12.8%.
    • Press Release
    | Mon, Aug. 8, 4:40 PM | 16 Comments
  • Sun, Aug. 7, 5:35 PM
  • Tue, Jun. 28, 2:57 AM
    • Endo International (NASDAQ:ENDP) has held discussions with P-E firms about potential asset sales to reduce its more than $8B debt pile.
    • Pfizer (NYSE:PFE) is investing $350M to build its first biotech center in China.
    • Horizon Pharma (NASDAQ:HZNP) has hired Bank of America to help it explore selling a significant equity stake that would bolster its balance sheet.
    | Tue, Jun. 28, 2:57 AM | 2 Comments
  • Fri, Jun. 17, 7:06 AM
    • Hill Rom Holdings (NYSE:HRC) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $62 (20% upside) from $54.
    • Arbutus Biopharma (NASDAQ:ABUS) upgraded to Neutral from Sell by Chardan. Price target is $3.25 (1% downside risk).
    • Achaogen (NASDAQ:AKAO) upgraded to Outperform from Neutral by Wedbush. Price target raised to $10 (111% upside) from $7.
    • PRA Health Sciences (NASDAQ:PRAH) upgraded to Overweight from Sector Weight by KeyBanc. Price target is $55 (25% upside).
    • Agios Pharmaceuticals (NASDAQ:AGIO) upgraded to Buy from Hold by JPMorgan. Price target raised to $62 (30% upside) from $50.
    • Quidel (NASDAQ:QDEL) upgraded to Outperform from Market Perform by Raymond James. Price target is $21.50 (20% upside).
    • Aptose Biosciences (NASDAQ:APTO) upgraded to Buy from Neutral by Roth Capital. Price target raised to $8 (186% upside) from $4.
    • Endologix (NASDAQ:ELGX) upgraded to Buy from Hold with a $15.50 (23% upside) price target by Canaccord Genuity.
    • Endo International (NASDAQ:ENDP) upgraded to Neutral from Underperform by Mizuho Securities. Price target raised to $16 (5% downside risk) from $13.
    • United Therapeutics (NASDAQ:UTHR) downgraded to Neutral from Buy by H.C. Wainwright. Price target lowered to $95 (11% downside risk) from $175.
    • Infinity Pharmaceuticals (NASDAQ:INFI) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $1 (32% downside risk) from $11.
    • LDR Holding (NASDAQ:LDRH) downgraded to Market Perform from Outperform by Cowen & Company.
    • Marinus Pharmaceuticals (NASDAQ:MRNS) downgraded to Perform from Outperform by Oppenheimer. $17 price target removed. Also downgraded to Sector Perform from Outperform by RBC Capital.
    • Mesoblast (NASDAQ:MESO) downgraded to Neutral from Outperform by Credit Suisse. Price target lowered to $5 (21% upside) from $10.
    • Revance Therapeutics (NASDAQ:RVNC) downgraded to Hold from Buy by Brean Capital. Price target removed.
    • OraSure (NASDAQ:OSUR) downgraded to Market Perform from Outperform by Raymond James. Price target is $8 (15% upside).
    | Fri, Jun. 17, 7:06 AM | 3 Comments
  • Wed, Jun. 15, 9:58 AM
    • The FDA has informed Endo International (ENDP +1.4%) unit Endo Pharmaceuticals that an Advisory Committee will meet in the fall to review and discuss its Supplemental New Drug Application (sNDA) seeing approval of an abuse-deterrent formulation of opioid pain med OPANA ER (oxymorphone HCl). The schedule means that the agency's current July 29 action date (PDUFA) will not be met. A decision should happen shortly after the meeting.
    • The abuse-deterrent version of OPANA ER is based on Grunenthal's INTAC technology which uses a high molecular weight polymer (polyethylene oxide) to harden pills making them resistant to crushing.
    | Wed, Jun. 15, 9:58 AM
  • Mon, Jun. 13, 1:17 PM
    • A Phase 2 clinical trial assessing BioSpecifics Technologies' (BSTC +3.4%) collagenase clostridium histolyticum (CCH) for the treatment of human lipoma successfully achieved its primary endpoint of reducing the visible surface area of the target lipomas compared to placebo. All secondary efficacy endpoints were also met.
    • Results from the 19-subject trial showed an 81.3% reduction in the visible surface area of the target lipoma in the CCH group compared to a 2.1% increase for placebo (p<0.0001) as measured by caliper six months following injection. In addition, 89.5% of CCH-treated patients were responders at month 6 versus 0% for placebo (p<0.0001).
    • No drug-related serious adverse events were reported and no participant dropped out of the trial. The most common adverse events were injection site-related (swelling, pain, itching).
    • CCH, administered directly into a lipoma via injection, potentially offers patients an alternative to surgery. Lipomas are benign encapsulated deposits of fat that appear as bulges under the skin. The cause is unknown but is believed to be hereditary.
    • The company intends to review the data with partner Endo International (ENDP +0.1%) who has the right to opt-in for this indication. If it exercises its option, BSTC will earn a cash payment, future milestones and royalties on net sales. Also, Endo would be responsible for future development costs.
    • CCH is currently marketed by Endo under the brand name XIAFLEX for the treatment Dupuytren's contracture and Peyronie's disease.
    | Mon, Jun. 13, 1:17 PM
  • Mon, Jun. 13, 12:10 PM
    • Adamas Pharmaceuticals (ADMS -1.3%) announces positive results from a Phase 2 proof-of-concept clinical trial assessing lead product candidate ADS-5102 in patients with multiple sclerosis (MS) who have trouble walking. According to the company, the data "suggests" that ADS-5102 was well-tolerated and had a significant impact on walking speed. It plans to present the results at an upcoming scientific conference.
    • The 60-subject randomized, double-blind, placebo-controlled trial evaluated a daily dose of 340 mg of ADS-5102 for four weeks. The key metric was the timed 25-foot walking test (T25FW) where treated patients showed a ~15% improvement in walking speed versus placebo (p<0.05) in the modified intent-to-treat population (n=56). Other walking performance measures were directionally consistent, which means that the results favored ADS-5102 but fell short of statistical significance.
    • Adverse events were consistent with the known safety profile of amantadine. The majority of participants experienced at least one adverse event (AE) with most being mild or moderate. Five patients in the ADS-5102 group discontinued treatment due to an AE, one due to a serious AE related to ADS-5102.
    • CEO Greg Went says, "We are now ready to speak with the FDA about a pivotal (Phase 3) registration program for impaired walking in people with MS."
    • ADS-5102 is an extended-release formulation of Parkinson's disease drug amantadine, originally approved by the FDA in November 2003 under the brand name Symmetrel, marketed by Endo Pharmaceuticals (ENDP).
    | Mon, Jun. 13, 12:10 PM
  • Fri, Jun. 10, 7:19 AM
    • Boston Scientific (NYSE:BSX) initiated with Buy rating and $26 (13% upside) price target by Guggenheim Securities.
    • Zimmer Biomet Holdings (NYSE:ZBH) initiated with Neutral rating and $140 (18% upside) price target by Guggenheim Securities.
    • Edwards Lifesciences (NYSE:EW) initiated with Neutral rating and $120 (18% upside) price target by Guggenheim Securities.
    • Oncobiologics (Pending:ONS) initiated with Buy rating and $15 (218% upside) price target by Cantor Fitzgerald.
    • Walgreens Boots Alliance (NASDAQ:WBA) reinstated with Buy rating and $95 (20% upside) price target by Bank of America.
    • Goldman Sachs initiates coverage of specialty pharma with a Neutral rating: Buy: Jazz Pharma (NASDAQ:JAZZ) - $196 (26% upside) price target, Horizon Pharma (NASDAQ:HZNP) - $24 (30% upside) price target; Neutral: Endo International (NASDAQ:ENDP) - $20 (11% upside) price target, Mallinckrodt (NYSE:MNK) - $73 (17% upside) price target, Momenta Pharmaceuticals (NASDAQ:MNTA) - $14 (19% upside) price target; Concordia Healthcare (NASDAQ:CXRX) - $32 (31% upside) price target; Sell: Impax Laboratories (NASDAQ:IPXL) - $33 (2% downside risk) price target.
    • Biocept (NASDAQ:BIOC) initiated with Buy rating and $1.20 (71% upside) price target by Roth Capital.
    • Seres Therapeutics (NASDAQ:MCRB) initiated with Outperform rating and $40 (22% upside) price target by Cowen & Company.
    • Omeros (NASDAQ:OMER) initiated with Buy rating and $21 (94% upside) price target by Cantor Fitzgerald.
    • Glaukos (NYSE:GKOS) initiated with Buy rating and $35 (30% upside) price target by Cantor Fitzgerald.
    • Shire plc (NASDAQ:SHPG) initiated with Overweight rating and GBX5,600 (34% upside) price target by Morgan Stanley.
    | Fri, Jun. 10, 7:19 AM